ClinicalTrials.gg
CompletedNCT00827242Updated Nov 17, 2010Results posted

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

A Phase 3 interventional study of Placebo and tadalafil in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 27 sites in 5 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2010-11-17.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
10th of 26
325 · median 258
Started
2009
with 4 others
Phase 3
10 of 26
none open now
Registered
6th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 10th largest by enrollment, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 6th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full, etc.)

03

Conditions studied

  • Benign Prostatic Hyperplasia

Keywords

  • Signs and Symptoms
  • Prostatic Hyperplasia
  • Hyperplasia
  • Genital Diseases, Male
  • Prostatic Diseases
  • BPH-LUTS
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men 45 years of age or older with Benign Prostatic Hyperplasia (BPH) also referred to as BPH-LUTS [lower urinary tract symptoms] based on the disease diagnostic criteria at the start of study.
  • Provide signed at the start of the study.
  • Have not taken Finasteride therapy for at least 3 months before study drug is dispensed and Dutasteride therapy for at least 6 months before study drug is dispensed.
  • Have not taken other BPH therapy (including herbal preparations), overactive bladder (OAB) therapy, or erectile dysfunction (ED) therapy for at least 4 weeks prior to study drug is dispensed.
  • Agree not to use any other approved or experimental pharmacologic BPH, OAB, or ED treatments anytime during the study
  • Have LUTS with a Total International Prostate Symptom Score (IPSS) greater than or equal to 13 when study drug is dispensed.
  • Have reduced peak urine flow rate when study drug is dispensed (measured by a special toilet equipment).
  • Demonstrate compliance with study drug administration requirements.

Exclusion criteria

Exclusion Criteria:

  • Treated with nitrates for a cardiac conditions.
  • Have unstable angina or angina that requires treatment.
  • Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).
  • Have very high or very low blood pressure
  • Have problems with kidneys, liver, or nervous system.
  • Have uncontrolled diabetes.
  • Have had a stroke or a significant injury to brain or spinal cord.
  • Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer (Prostate-Specific Antigen [PSA] greater than 10 nanograms/milliliter [ng/ml] at the start of study).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    Tadalafil

    Drug: tadalafil

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugPlacebo

    Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.

  • Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.

    Also known as: Cialis, LY450190

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)

    The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline to 4 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index

    The BPH Impact Index (BII) is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 4 weeks

  2. Change From Baseline to 12 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index

    The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  3. Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore

    IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  4. Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore

    IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  5. Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Nocturia Question

    Measures nocturia (the need to get up at night to urinate). Scores range from 0 (few episodes of nocturia) to 5 (frequent episodes of nocturia). LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  6. Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index

    Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  7. Patient Global Impression of Improvement (PGI-I), Number of Participants in 7 Response Categories

    A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).

    Time frame: 12 weeks

  8. Clinical Global Impression of Improvement (CGI-I), Number of Participants in 7 Response Categories

    Measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).

    Time frame: 12 weeks

  9. Change From Baseline to 1 Week, International Prostate Symptom Score (IPSS)

    The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 1 week

  10. Change From Baseline to 4 Weeks, International Prostate Symptom Score (IPSS)

    The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 4 Weeks

  11. Change From Baseline to 12 Weeks, International Index of Erectile Function (IIEF)- Erectile Function (EF) Domain Scores

    Self-reported EF. Scores range from 0 (low or no EF) to 5 (high EF) on 6 questions (1-5, 15 of the IIEF). EF Domain scores range from 0 to 30. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  12. Change From Baseline to 12 Weeks, Peak Flow Rate (Qmax) by Uroflowmetry

    Qmax was defined as the peak urine flow rate (measured in milliliters per second \[mL/sec\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>=125 mL.

    Time frame: Baseline, 12 weeks

  13. Change From Baseline to 12 Weeks, Mean Flow Rate (Qmean) by Uroflowmetry

    Qmean was defined as the mean urine flow rate (measured in mL/sec using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 mL and the Vcomp was \>=125 mL.

    Time frame: Baseline, 12 weeks

  14. Change From Baseline to 12 Weeks, Voided Volume (Vcomp) by Uroflowmetry

    Vcomp was defined as the volume of urine voided (measured in mL using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 mL and the Vcomp was \>=125 mL.

    Time frame: Baseline, 12 weeks

  15. Change From Baseline to 12 Weeks, Postvoid Residual (PVR) Volume

    The amount of urine remaining in the bladder after void completion.

    Time frame: Baseline, 12 weeks

07

Results

Posted Nov 17, 2010

Participant flow

Participant flow — Overall Study
MilestoneTadalafilPlacebo
Started161164
Completed148152
Not completed1312
Withdrew: Withdrawal by subject24
Withdrew: Protocol violation13
Withdrew: Lost to follow-up03
Withdrew: Adverse event excluding death21
Withdrew: Entry criteria not met41
Withdrew: Physician decision20
Withdrew: Death10
Withdrew: Lack of efficacy10

Outcome measures

PrimaryChange From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)

The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)
Units on a ScaleTadalafilPlacebo
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)-5.6 ± 0.47-3.6 ± 0.47
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.004 (The p-value associates with LS Mean difference of changes from baseline to 12 weeks between treatment groups for IPSS. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -1.9
SecondaryChange From Baseline to 4 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index

The BPH Impact Index (BII) is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 4 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index
Units on a ScaleTadalafilPlacebo
Change From Baseline to 4 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index-1.8 ± 0.18-1.2 ± 0.18
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.029 (The p-value associates with LS Mean difference of changes from baseline to 4 weeks between treatment groups for BII. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -0.6
SecondaryChange From Baseline to 12 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index

The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 12 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index
Units on a ScaleTadalafilPlacebo
Change From Baseline to 12 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index-1.8 ± 0.21-1.3 ± 0.21
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.057 (The p-value associates with LS Mean difference of changes from baseline to 12 weeks between treatment groups for BII. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -0.6
SecondaryChange From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore

IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore
Units on a ScaleTadalafilPlacebo
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore-2.3 ± 0.22-1.3 ± 0.21
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.002 (The p-value associates with LS Mean difference of changes from baseline to 12 weeks between treatment groups for IPSS storage subscore. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -0.9
SecondaryChange From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore

IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore
Units on a ScaleTadalafilPlacebo
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore-3.3 ± 0.31-2.3 ± 0.31
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.020 (The p-value associates with LS Mean difference of changes from baseline to 12 weeks between treatment groups for IPSS voiding subscore. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -1.0
SecondaryChange From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Nocturia Question

Measures nocturia (the need to get up at night to urinate). Scores range from 0 (few episodes of nocturia) to 5 (frequent episodes of nocturia). LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Nocturia Question
Units on a ScaleTadalafilPlacebo
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Nocturia Question-0.5 ± 0.08-0.4 ± 0.08
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.233 (The p-value associates with LS Mean difference of changes from baseline to 12 weeks between treatment groups for IPSS nocturia question. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -0.1
SecondaryChange From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index

Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index
Units on a ScaleTadalafilPlacebo
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index-1.0 ± 0.10-0.7 ± 0.10
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.013 (The p-value associates with LS Mean difference of changes from baseline to 12 weeks between treatment groups for IPSS QoL Index. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -0.4
SecondaryPatient Global Impression of Improvement (PGI-I), Number of Participants in 7 Response Categories

A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).

Time frame:
12 weeks
Reported as:
Number · Participants
Patient Global Impression of Improvement (PGI-I), Number of Participants in 7 Response Categories
ParticipantsTadalafilPlacebo
7-Very Much Worse10
6-Much Worse56
5-A Little Worse44
4-No Change3057
3-A Little Better5753
2-Much Better4632
1-Very Much Better126
Statistical analysis
  • Tadalafil vs Placebo · Cochran-Mantel-Haenszel · p = 0.021 (The p-value associates with difference between treatment groups for the 7 response categories.)Results were adjusted for baseline LUTS severity (moderate \[total IPSS \< 20\]; severe \[total IPSS \>= 20\]
SecondaryClinical Global Impression of Improvement (CGI-I), Number of Participants in 7 Response Categories

Measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).

Time frame:
12 weeks
Reported as:
Number · Participants
Clinical Global Impression of Improvement (CGI-I), Number of Participants in 7 Response Categories
ParticipantsTadalafilPlacebo
7-Very Much Worse00
6-Much Worse52
5-A Little Worse410
4-No Change3659
3-A Little Better5855
2-Much Better3925
1-Very Much Better137
Statistical analysis
  • Tadalafil vs Placebo · Cochran-Mantel-Haenszel · p = 0.009 (The p-value associates with difference between treatment groups for the 7 response categories.)Results were adjusted for baseline LUTS severity (moderate \[total IPSS \< 20\]; severe \[total IPSS \>= 20\]
SecondaryChange From Baseline to 1 Week, International Prostate Symptom Score (IPSS)

The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 1 week
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 1 Week, International Prostate Symptom Score (IPSS)
Units on a ScaleTadalafilPlacebo
Change From Baseline to 1 Week, International Prostate Symptom Score (IPSS)-3.4 ± 0.35-2.7 ± 0.35
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.146 (The p-value associates with LS Mean difference of changes from baseline to 1 week between treatment groups for IPSS. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -0.7
SecondaryChange From Baseline to 4 Weeks, International Prostate Symptom Score (IPSS)

The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 4 Weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 4 Weeks, International Prostate Symptom Score (IPSS)
Units on a ScaleTadalafilPlacebo
Change From Baseline to 4 Weeks, International Prostate Symptom Score (IPSS)-5.3 ± 0.43-3.5 ± 0.43
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.003 (The p-value associates with LS Mean difference of changes from baseline to 4 weeks between treatment groups for IPSS. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): -1.8
SecondaryChange From Baseline to 12 Weeks, International Index of Erectile Function (IIEF)- Erectile Function (EF) Domain Scores

Self-reported EF. Scores range from 0 (low or no EF) to 5 (high EF) on 6 questions (1-5, 15 of the IIEF). EF Domain scores range from 0 to 30. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Units on a Scale
Change From Baseline to 12 Weeks, International Index of Erectile Function (IIEF)- Erectile Function (EF) Domain Scores
Units on a ScaleTadalafilPlacebo
Change From Baseline to 12 Weeks, International Index of Erectile Function (IIEF)- Erectile Function (EF) Domain Scores6.7 ± 0.802.0 ± 0.82
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (The p-value associates with LS Mean difference of changes from baseline to 12 weeks between treatment groups for IIEF-EF domain score. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.) · Mean difference (final values): 4.7
SecondaryChange From Baseline to 12 Weeks, Peak Flow Rate (Qmax) by Uroflowmetry

Qmax was defined as the peak urine flow rate (measured in milliliters per second \[mL/sec\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>=125 mL.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · mL/sec
Change From Baseline to 12 Weeks, Peak Flow Rate (Qmax) by Uroflowmetry
mL/secTadalafilPlacebo
Change From Baseline to 12 Weeks, Peak Flow Rate (Qmax) by Uroflowmetry1.6 ± 4.641.1 ± 4.64
Statistical analysis
  • Tadalafil vs Placebo · ranked ANOVA · p = 0.300 (The p-value associates with mean difference of changes from baseline to 12 weeks between treatment groups for Qmax. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.)
SecondaryChange From Baseline to 12 Weeks, Mean Flow Rate (Qmean) by Uroflowmetry

Qmean was defined as the mean urine flow rate (measured in mL/sec using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 mL and the Vcomp was \>=125 mL.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · mL/sec
Change From Baseline to 12 Weeks, Mean Flow Rate (Qmean) by Uroflowmetry
mL/secTadalafilPlacebo
Change From Baseline to 12 Weeks, Mean Flow Rate (Qmean) by Uroflowmetry0.6 ± 2.930.5 ± 2.79
SecondaryChange From Baseline to 12 Weeks, Voided Volume (Vcomp) by Uroflowmetry

Vcomp was defined as the volume of urine voided (measured in mL using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 mL and the Vcomp was \>=125 mL.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · mL
Change From Baseline to 12 Weeks, Voided Volume (Vcomp) by Uroflowmetry
mLTadalafilPlacebo
Change From Baseline to 12 Weeks, Voided Volume (Vcomp) by Uroflowmetry16.9 ± 88.743.9 ± 105.68
SecondaryChange From Baseline to 12 Weeks, Postvoid Residual (PVR) Volume

The amount of urine remaining in the bladder after void completion.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · mL
Change From Baseline to 12 Weeks, Postvoid Residual (PVR) Volume
mLTadalafilPlacebo
Change From Baseline to 12 Weeks, Postvoid Residual (PVR) Volume8.8 ± 56.404.5 ± 66.71
Statistical analysis
  • Tadalafil vs Placebo · ranked ANOVA · p = 0.500 (The p-value associates with mean difference of changes from baseline to 12 weeks between treatment groups for PVR volume. Under the pre-specified fixed sequence testing procedure, the significance level of 0.05 is used for assessment.)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil—2/161 (1.2%)41/161 (25.5%)
Placebo—0/164 (0%)36/164 (22%)
Most frequent serious events
Most frequent serious events
EventTadalafilPlacebo
Acute myocardial infarctionCardiac disorders1/1610/164
EndocarditisInfections and infestations1/1610/164
Most frequent other events
Showing 10 of 60
Most frequent other events
EventTadalafilPlacebo
HeadacheNervous system disorders6/1611/164
Back painMusculoskeletal and connective tissue disorders5/1614/164
NasopharyngitisInfections and infestations3/1613/164
ArthralgiaMusculoskeletal and connective tissue disorders3/1610/164
DizzinessNervous system disorders3/1610/164
HypertensionVascular disorders3/1613/164
InfluenzaInfections and infestations1/1613/164
Gastrooesophageal reflux diseaseGastrointestinal disorders2/1610/164
SinusitisInfections and infestations2/1610/164
MyalgiaMusculoskeletal and connective tissue disorders2/1610/164

Baseline characteristics

Age Continuous
Age Continuous(years)TadalafilPlaceboTotal
Mean65.1 ± 8.4364.6 ± 10.0364.9 ± 9.26
Sex: Female, Male
Sex: Female, Male(Participants)TadalafilPlaceboTotal
Female000
Male161164325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TadalafilPlaceboTotal
Hispanic or Latino464490
Not Hispanic or Latino115120235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TadalafilPlaceboTotal
American Indian or Alaska Native9817
Asian202
Black or African American358
White146150296
More than one race112
Region of Enrollment
Region of Enrollment(participants)TadalafilPlaceboTotal
United States5052102
South America434386
Europe6869137
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram (kg)/meter (m)^2)TadalafilPlaceboTotal
Mean27.1 ± 3.8228.4 ± 4.2127.7 ± 4.07
Baseline Lower Urinary Tract Symptoms (LUTS) Severity
Baseline Lower Urinary Tract Symptoms (LUTS) Severity(participants)TadalafilPlaceboTotal
Moderate100110210
Severe6154115
Peak Urine Flow Rate (Qmax) Category
Peak Urine Flow Rate (Qmax) Category(participants)TadalafilPlaceboTotal
<10 mL/sec5462116
10-15 mL/sec7867145
>15 mL/sec202444

9 further baseline measures are reported on the registry.

08

Study locations

27 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huntsville, Alabama 35801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Middlebury, Connecticut 06762, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sarasota, Florida 34237, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Roswell, Georgia 30076, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bayshore, New York 11706, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10016, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Williamsville, New York 14221, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durham, North Carolina 27710, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbus, Ohio 43220, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37920, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Virginia Beach, Virginia 23454, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, 1405, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13465, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20354, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marburg, 35039, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Muehlacker, D-75417, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oranienburg, D-16515, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milan, 20132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Napoli, 80131, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orbassano, 10043, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00161, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 10700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64040, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saltillo, 25210, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zapopan, 45040, Mexico
09

References and documents

Publications

  • Vlachopoulos C, Oelke M, Maggi M, Mulhall JP, Rosenberg MT, Brock GB, Esler A, Buttner H. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. Int J Clin Pract. 2015 Dec;69(12):1496-507. doi: 10.1111/ijcp.12722. Epub 2015 Aug 24. PubMed 26299520 ↗
  • Porst H, Kim ED, Casabe AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011 Nov;60(5):1105-13. doi: 10.1016/j.eururo.2011.08.005. Epub 2011 Aug 12. PubMed 21871706 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2009
First posted
Jan 22, 2009
Start
Jan 2009
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Nov 17, 2010
Last update
Nov 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00827242
First posted
Jan 22, 2009
Start date
Jan 2009
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Nov 17, 2010
Last update
Nov 17, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion